BioNTech has completed its acquisition of CureVac, bringing together two leading German mRNA technology firms. Approximately 86.75% of CureVac shares were tendered during the offer period, and BioNTech plans to finalize the compulsory acquisition of the remaining shares by January 2026. The transaction aims to strengthen BioNTech's capabilities in mRNA design, delivery, and manufacturing, supporting its oncology strategy and expanding its portfolio of mRNA-based therapeutics. CureVac will continue to operate under its existing organizational processes as BioNTech conducts further strategic and operational analyses to define the future setup.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001145585-en) on December 18, 2025, and is solely responsible for the information contained therein.